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Surgery remains the mainstay of curative treatment for primary rectal cancer. For mid 
and low rectal tumors, optimal oncologic surgery requires total mesorectal excision 
(TME) to ensure the tumor and locoregional lymph nodes are removed. Adequacy of 
surgery is directly linked to survival outcomes and, in particular, local recurrence. From 
a technical perspective, the more distal the tumor, the more challenging the surgery 
and consequently, the risk for oncologically incomplete surgery is higher.  
TME can be performed by an open, laparoscopic, robotic or transanal approach. There 
is a lack of consensus on the ‘gold standard’ approach with each of these options 
offering specific advantages. The International Symposium on the Future of Rectal 
Cancer Surgery was convened to discuss the current challenges and future pathways of 
the four approaches for TME. This article reviews the findings and discussion from an 




What does this paper add to the existing literature? 
In the treatment of rectal cancer, an optimal surgical dissection provides improved 
locoregional control. Which surgical technique is the best option is still under debate. 
This paper overviews the current state of rectal cancer surgery from an expert point of 












Colorectal cancer is the third most commonly diagnosed malignancy worldwide and 
the third leading cause of cancer death in the USA. Rectal cancer accounts for 
approximately one third of all colorectal cancers 1. Since the early 1990s, total 
mesorectal excision (TME) has remained the gold standard surgical treatment for 
rectal cancer following Heald’s detailed publication of the technique in 1986 2. In the 
era of the multidisciplinary approach, the quality of the TME has been shown to be a 
significant prognostic factor for cancer-specific survival 3, 4, 5. The TME technique has 
evolved from traditional ‘open’ to minimal access approaches, such as laparoscopic, 
robotic and more recently, transanal techniques. However, the acceptance of one as 
better or even equivalent to the others remains a matter of debate. Issues such as case 
selection, morbidity and recovery, histopathology, oncology, functional outcomes and 
costs need to be analysed.  
 On December 9th 2016, The International Symposium on the Future of Rectal 
Cancer Surgery took place in London. This unique, interactive event was made freely 
available to viewers around the world through the online educational platform 
Advances in Surgery (AIS) Channel®. A multidisciplinary expert panel of rectal cancer 
clinicians presented the latest trial data and engaged in discussion for the role of the 
four different approaches in the treatment of rectal cancer, based on their experience 
and best evidence. Expert surgical teams performed live simultaneous demonstration 
of each technique with live commentary from various international experts in 
attendance. This was also followed by a live macroscopic assessment of the specimens 
by leading pathologists.  
The aim of this article is to provide the reader with an overview of the 
proceedings of this conference, highlighting the main areas of discussion, debate and 
controversy in the treatment of patients with rectal cancer.  
 
METHODS 
The coordinating authors (FBDL and SC) invited the panel of experts who had actively 
participated in the symposium to provide a short summary of each of their 
presentations. These summaries were merged and edited to account for areas of 
overlap and redundancy. All authors were subsequently given the opportunity to read 
and edit the merged version of the manuscript to ensure that all expert opinions were 
appropriately conveyed in the final version. 
 
SYMPOSIUM SUMMARIES 
1. Importance of TME technique: anatomical considerations along the mesorectal 
plane. RJ Heald 
TME was a milestone in the history of cancer surgery as it was the first en-bloc excision 
for cancer whose boundaries were conceptually and practically founded in 
embryology. An unexpectedly large improvement in local recurrence rates followed 
the initial application of the idea of TME to surgical practice – albeit imperfectly 
implemented in the early stages.  This pointed to a fundamental truth, now recognized 
as relevant to all visceral cancers – that embryologically defined envelopes of tissue 
with surgical and MRI definable margins and recognizably shiny surfaces, present the 
surgeon with particular opportunities for cure – exposing the exciting reality that initial 
cancer spread is often confined to these envelopes following their lymphovascular 
supply. Despite the importance of a perfect TME being widely understood, mesorectal 
residues are still the principal source of local recurrence in most 
countries.  Complementary to this “envelope concept” is respect for the surrounding 
layers and an understanding of their anatomy, not only for more actual “cures” but 
also for the preservation of the important autonomic functions that we can group 
together as “Pelvic Happiness” – sexual function, continence, etc.  The innermost 
dissection plane between the covering layer of the gut envelope and the lining layer of 
the parietes is “holy”: the surgeon must constantly follow this innermost plane to 
achieve an optimal operation. The objective of the newly adopted transanal TME 
(TaTME) is identical to that for conventional approaches. The first step is to identify 
the “holy” plane, which is the “innermost dissectable plane”. Subsequently, providing 
traction and counter-traction to identify the white areolar tissue characteristic of an 
embryological plane allows for the initiation of sharp dissection on the “yellow side of 
the white” (the innermost mesorectal yellow). When coming from above, identifying 
this plane is often best achieved around the pedicle above the pelvic brim. Of 
importance, there are key areas where this dissection must be stressed through 
various educational aids such as video based education. An example of this is the 
location at which the enveloping fascia can be less clear at the junction with the 
inferior hypogastric plexus, which has strong implications on erection and ejaculation 
in males.  
All surgeons accept that the deep pelvis, especially in a large male patient, 
provides the greatest challenge. There are two basic dimensional issues– the difficult 
areas are far down when approached from above and much closer from below but the 
angles are also more acute from below. Furthermore it is more difficult to push the 
tapering mesorectum up from within the encompassing pelvic floor than to draw it 
gradually out from above whilst opening the planes to be dissected.   
The crucial layers low down with potential surgical planes between them are 
complicated by two septa – Denonvilliers anteriorly, and Waldeyer posteriorly. 
Denonvilliers’ “aponévrose” (as he originally described it in 1835) is a trapezoidal 
collagenous sheet, tapering medially as it descends, usually adherent to the anterior 
aspect of the mesorectum and intervening between it and the seminal vesicles 
6.  Dissection from above is usually in front of Denonvilliers because the plane is easier, 
and for anterior cancers this must be favoured anyway for a safer margin. If thus 
incorporated with the specimen, it must then be incised in a U shape to enter the 
space behind the prostate, carefully preserving the nerves laterally.  
Waldeyer is a thickening of the presascral fascia, which has a variable 
propensity for becoming adherent about half way down the sacrum to the mesorectal 
fascia, thus potentially dividing the mesorectal/pre-sacral space into two spaces. At 
this point Waldeyers creates an obstacle for the surgeon dissecting downwards from 
above and this adherence has been called the Recto-sacral Fascia or Ligament. Faced 
with this, the abdominal surgeon usually elects to cut through it entering into a space 
with bare coccyx and the presacral venous plexus. It is important in the transanal 
approach not to proceed posterior to this layer from below, as it may lead to the 
lateral compartments with the potential for bleeding, nerve injury, and even dissecting 
anterior to the prostate, potentially injuring the urethra. As such, it must be 
emphasized that the “Holy plane” is the innermost dissectable plane that will optimize 
nerve preservation whilst still delivering perfect TME specimens – all dissected around 
the “yellow side of the white”, i.e. dissection on the mesorectal fat plane leaving 
behind the white retroperitoneal fascial covering of all the surrounding organs. The 
transanal approach seems to offer a new potential for recognizing and dissecting 
inside the two layers – Denonvilliers’ and Waldeyers’ – and thus offering an extra 
potential for the preservation of autonomic function. 
 
2. Four approaches for the treatment of rectal cancer: advantages and disadvantages?  
Open TME. B Moran  
The main focus in cancer surgery is to optimize cure and to maximise quantity and 
quality of life with and minimization of treatment complications. There are particular 
issues with rectal cancer due to access to the depths of the pelvis and proximity to 
important surrounding structures such as the genito-urinary systems and the anal 
sphincters in the restricted space of the bony pelvis. For these reasons there has, and 
always will be, a conflict between wide excision of the tumor and preservation of 
tissue to maximise bowel, bladder and sexual function. TME was the real advance in 
our surgical approach because it balances optimal oncological resection with maximal 
functional preservation. More recently, optimal imaging by MRI has allowed detailed 
planning prior to surgery, together with the addition of preoperative radiotherapy in 
selected cases. The original concept of TME was developed in the era of open surgery 
and focused on the quality of the specimen assessed by macroscopic appearance 
(Quirke TME Grading) 7 and a microscopic assessment of the outermost tumor margin 
(Quirke Circumferential Resection Margin) 8, both being prognostic factors for 
locoregional recurrence 3, 4. 
There have been a number of developments in alternative approaches to rectal 
cancer that capitalize on minimal access techniques and potentially improved 
visualization of the pelvis. Well-designed prospective comparative studies have failed 
to consistently demonstrate an advantage to any technique over what remains the 
standard of care, open surgery 9-12. Open approaches remain the technique of choice 
for surgeons who find themselves most effectively able to provide an oncologically 
sound resection of a rectal cancer, with complete mesorectal excisions, negative 
circumferential and distal resection margins and a preservation of autonomic nerve 
function. Additionally, tumors that have a component of adjacent organ, or side-wall, 
involvement, though nevertheless resectable, are often approached with an open 
approach given the need for tactile sensation. This allows optimization of intra-
operative decision making to produce clear margins. In the meantime, technology and 
concepts have evolved and we are now in the era of laparoscopic, robotic and TaTME. 
Proponents of robotic and TaTME claim advantages, not only over open surgery, but 
also compared with laparoscopic surgery. Amongst all of this evolving technology, 
three statements should be kept in mind: (1) laparoscopic, robotic and TaTME are 
access techniques and should be classified as “minimal access” in that “minimally 
invasive” is a misnomer; (2) the focus should be on optimal outcomes which 
incorporates the appropriate selection of cases, familiarization with technology and 
surgical expertise with the technique of TME chosen to allow for the goal of optimal 
specimen quality with clear margins; (3) we should remain cognizant of the fact that 
the surgeon’s technical abilities produce the patient outcomes, not the technique 
(“Laparoscopes and robots don’t operate, surgeons do “ 13). 
We should embrace new technology, be part of the future, but select the right 
patient for the right technique and never abandon the gold standard technique of 
open surgery, nor be afraid to convert a minimal access technique to open if vision, 
adequate retraction, tactile sensation or other benefits are optimized by an open 
procedure. 
 
Laparoscopic TME. Y Panis 
Since the early 2000s, laparoscopic resection of colon cancer has been shown to have 
benefits compared to laparotomy. Long-term oncological safety of colon cancer 
laparoscopic surgery has also been reported in meta-analyses 14.  
The anatomical restrictions and technical detail of a TME for rectal cancer has 
meant a longer path to demonstrate the safety of a laparoscopic approach. A 
laparoscopic approach can provide obvious theoretical advantages with a magnified 
view allowing a precise dissection in a narrow pelvic space, leading to the possibility of 
better autonomic nerve sparing strategies. The restrictions of the bony pelvis, the 
technical expertise necessary to expose the appropriate planes and the associated 
perioperative, functional and oncologic morbidity of a poor resection have limited the 
adoption of this technique to subspecialized higher volume surgeons. 
In the recent years, the short and long-term results of several randomized 
clinical trials have been published and demonstrated the safety of a laparoscopic 
approach to TME, with short-term benefits and similar oncological outcomes 15, 16, 17, 18. 
However, two recent randomized trials have reported controversial results in this 
discussion of laparoscopic versus open rectal cancer surgery. These two studies, 
namely ALaCaRT (Australasian Laparoscopic Cancer of the Rectum) and ACOSOG 
(American College of Surgeons Oncology Groups) Z6051 were similarly designed non-
inferiority trials that utilized a new trichotomous composite outcome based on the 
completeness of the mesorectal excision as well as the negativity of the 
circumferential and distal resection margins 19, 20. The lack of validation, and therefore 
the unestablished clinical and oncologic significance of this primary outcome, has 
introduced some hesitance in the oncology community in accepting these trials results, 
given that both trials failed to demonstrate a non-inferiority of the laparoscopic 
approach relative to the traditional open approach. The implications that these 
pathologic outcomes will have on survival data are expected to be reported in future 
publications from these groups. It can be seen that meta-analyzing these trials would 
be difficult to interpret given the different designs as well as the differing primary 
outcomes and therefore ways in which trials were powered. In table 1, the most 
important outcomes of the above mentioned randomized clinical trials are reported. 
Recently, a meta-analysis of 27 studies and 10861 patients found no difference in 
terms of rate of complete resection, mesorectal excision quality and local recurrence 
between laparoscopic and open TME 21. 
Laparoscopic TME results in enhanced recovery compared with open TME 15. 
Nevertheless, in the COLOR II trial neither the health-related quality of life nor the 
genitourinary dysfunction were improved by the laparoscopic approach 22, suggesting 
that the clinical benefits of laparoscopy persist only in the short postoperative period.  
 
Robotic TME. J Khan 
Despite the advantages of laparoscopic surgery, the technique has its own limitations 
with a two-dimensional view, limitations in range of movements, fulcrum effects of 
various bony aspects of the pelvis resulting in problems in access and exposure, 
especially in the pelvic depths of patients with large tumors and obese body habitus. 
All of this leads to an extended learning curve for the surgeon.  
The robotic approach seems to be a valid alternative to combat some of the 
issues encountered with laparoscopy. Three-dimensional views, endowristed 
instrumentation and a stable camera platform make it a very attractive option for the 
surgeon. This may translate into improved tissue dissection, accurate cancer clearance, 
precision surgery with minimal collateral damage and excellent functional outcomes 
for patients. For an experienced laparoscopic colorectal surgeon the learning curve for 
robotics is minimal, and can be as little as 10-15 cases 23. Operative costs and reports 
of longer operative times have been the two main deterrents for the uptake of this 
technology amongst many colorectal surgeons.  
A robotic approach to the pelvis for rectal cancer is feasible and safe, and the 
initial results are very encouraging 24. Large series from high volume centres might 
provide the evidence for its efficacy and cost effectiveness. The preservation of sexual, 
urological and bowel function, and decreased fatigue and stress for the surgeon, are 
going to be major stand out points encouraging surgeons to embrace this technology 
for the management of rectal cancer. 
Provisional results from the multi-national ROLARR trial found no difference in 
pathological circumferential resection margin (pCRM) positive rate (5.1% in the robotic 
group vs. 6.3% in the laparoscopic group (OR 0.79, 95% CI 0.35 – 1.76)) and 
postoperative complications (33.1% vs. 31.7%) 25. Anastomotic complications occurred 
in 2.6% and 3.0% of laparoscopic and robotic cases respectively. Thirty-day mortality 
was less than 1% in both groups. Conversion to open, which was the primary outcome 
for this study, was necessary in 8.1% for robotic and 12.3% for laparoscopic TMEs (p = 
0.16). A priori subgroup analysis showed fewer rate of conversion in men and obese 
patients undergoing robotic resection, suggesting a benefit for the robotic TME in 
these cohorts of patients. 
 
Transanal TME. AM Lacy 
Performance of an optimal TME mainly depends on the anatomy of the patient, tumor 
characteristics, response to neoadjuvant therapy and a composite of surgical 
technique and surgical team skills. Working in the low pelvis, especially in male and 
obese patients, increases the difficulty of the procedure and threatens the fulfilment 
of a complete mesorectal excision with negative margins. This fact might restrict the 
quality of the TME when it is approached transabdominally, but could be less 
challenging when approached transanally. Potentially, TaTME allows for an increased 
quality of TME in mid and low rectal tumors, together with a lower rate of abdominal 
conversion and permanent stoma. Whiteford et al were the first to performing a 
natural-orifice transanal endoscopic rectosigmoid resection in a human cadaver 26, 
while Atallah and colleagues established the feasibility and safety of transanal 
minimally invasive surgery (TAMIS) 27. This set the stage for a cadaveric series that was 
the premise for the performance of the first TaTME in Barcelona 28.  
 TaTME can be performed either by one-team or a two-team approach, the 
latter being called the “Cecil approach” 29. Where TaTME is to be performed by a one-
team approach starting with the abdominal phase is often recommended in order to 
avoid retropneumoperitoneum that might make the laparoscopic resection harder. 
The two-team approach is strongly advocated by the TaTME community. It allows for 
shorter operative times, improved visualization, better traction and counter-traction 
while facilitating the ultimate goal of this approach in optimizing the oncologic 
outcomes and functional preservation in rectal cancer surgery 29, 30. Three-dimensional 
cameras and insufflators with continuous flow and smoke evacuation have further 
optimized the safety and quality of these resections. However, potentially the most 
important step of the transanal approach is a correct closure of the bowel lumen so as 
to follow an adequate plane of mesorectal dissection. This technique is a high-stakes 
procedure with multiple potential pitfalls and complications, both functionally and 
oncologically. As such, it is strongly recommended that surgeons ensure they have an 
adequate expertise in laparoscopic and transanal surgery, following an established 
training process 31 and ensure that early experiences are proctored for optimal 
collegial support.  
Data from the international TaTME registry showed pCRM involvement in 2.4% 
of cases. Composite poor pathological outcome was seen in 7.4%. Early anastomotic 
leaks occurred in 6.7%. Post operative morbidity was 32.6% and the mortality rate was 
2.6%. Conversion was necessary in 6.3% during the abdominal part of the procedure 
and 2.8% for the perineal approach 32. The data suggests that TaTME is feasible, safe, 
and could result in improved oncological outcomes compared to conventional 
approaches to TME.  
 3. Do the results of TME vary by technique? M Berho 
One of the most important functions of the pathologist at the time of examining rectal 
cancer specimens is that of an auditor. It has been shown that certain macroscopic 
features actually reflect the quality of the surgery performed. These features can be 
easily recognized by most pathologists at the time of gross examination and include (1) 
the integrity of the mesorectum, (2) the status of the resected margins and (3) the 
number of dissected lymph nodes. 
 
Integrity of the mesorectum: the integrity of the mesorectum is directly related to the 
plane at which the surgeon performs dissection of the rectum and the perirectal soft 
tissue from the pelvis, thus the plane of surgery can be mesorectal, intramesorectal, or 
muscularis propria as delineated by Quirke and colleagues 7 (Figure 1). 
 
Resection margins: the concept of distal tumor spread is presence of tumor cells within 
the mesorectum or rectum, distal to the level of the tumor. Several studies 
demonstrated that the presence of tumor distal spread beyond 2 cm is exceedingly 
rare 33, 34. As a result of this discovery, distal margins of 2 cm became generally 
accepted. More recently, with the introduction of surgical techniques such as double 
stapling as well as neoadjuvant chemoradiation (nCRT) and the widespread use of 
TME, 1 cm or sub-centimetre distal margins have gained greater approval. The 
importance of the CRM has been demonstrated by Quirke in a landmark study 
published in 1986, where the high incidence of local recurrence in patients with rectal 
cancer was directly related to the involvement of the circumferential (radial) margin of 
resection (CRM) rather than the distal margin 4. Numerous subsequent studies have 
confirmed that the presence of tumor ≤1 mm from the CRM adversely affects 
outcomes both at the local and systemic levels. There are three basic mechanisms of 
CRM involvement: 1) direct tumor extension; 2) foci of vascular/perineural invasion or 
tumor deposit; and 3) positive lymph node. Although there are currently no published 
series addressing the prognostic significance of each of these events, it may appear 
that direct extension of the tumor into the CRM would carry a more ominous 
prognosis. Several factors have been associated with a positive CRM including large 
and deep tumors, vascular and perineural invasion, poor tumor differentiation, 
advanced age, and mesorectal quality based on the quality of the surgical resection. 
The latter of these variables has a significant influence in the status of the CRM, 
logically; those specimens with incomplete peritumoral mesorectums have a higher 
risk of a positive CRM. 
 
Lymph node evaluation: although the adverse impact of lymph node metastasis is well 
known, the total number of dissected lymph nodes, regardless of the status (positive 
or negative), also influences the outcome of patients with colorectal cancer; the 
reasons for this remains unclear. It is important to point out that the rectum inherently 
contains fewer and smaller lymph nodes compared to other segments of the intestinal 
tract. In addition, factors including obesity, male gender, advanced age and 
neoadjuvant radiation have all been associated with a decreased number of lymph 
nodes 35. Conversely, tumor features such as depth of invasion into the rectal wall and 
poor differentiation have been correlated with higher node yield. Certainly, the 
number of lymph nodes evaluated also reflects the quality of the surgery performed by 
the surgeon as well as the diligence and effort of the dissecting pathologist. In cases of 
an optimal TME, the lymph node harvest depends entirely on meticulous work by the 
pathologist. Although lymph node dissection from rectal cancer specimens is 
traditionally carried out by a combination of palpation and visualization of the 
mesorectal tissue, several auxiliary techniques have been developed to further 
increase nodal yields. 
 
4. Choosing the optimal technique to optimize patient outcomes. P Tekkis 
Over time, pCRM involvement and conversion rates in laparoscopic surgery appear to 
have decreased. These have become the new benchmark in rectal cancer surgery. The 
improvements are related to advances in neoadjuvant treatment as well as surgical 
techniques. Likewise, reduction in clinical anastomotic leak rates may be the result of 
better patient selection for defunctioning stoma in addition to improved stapling 
devices and assessments of anastomotic perfusion. Short-term morbidity and mortality 
rates have remained the same, regardless of surgical approach. This may reflect the 
inherent challenges posed by patient and cancer characteristics that could not be 
mitigated by evolving of surgical techniques. 
Existing level-1 evidence has suggested that laparoscopic, robotic and transanal 
approaches to TME are safe alternatives to open surgery. This evidence does not help 
the surgeon decide on the most appropriate approach to ensure best clinical outcomes 
for an individual patient. It is important to note that other factors affect clinical 
outcomes in rectal cancer. The Mercury II study showed that tumor characteristics 
greatly influence the risk of pCRM involvement 36. In a cohort of patients 
predominantly undergoing open TME, pCRM was positive in 9.0% of cases. This varied 
significantly based on tumor features on MRI: extra mural vascular invasion, anterior 
tumors, low tumors, and tumors involving “at risk” planes. The risk of pCRM 
involvement ranged from 2.27% in tumors without risk factors to 53% when all four 
risk factors were present.  
Evidence is needed to help the surgeon select the best surgical technique for 
each case based on patient and tumor characteristics. For example, does the robotic 
approach offer most benefit for upper rectal cancer in obese male patients? Or is 
TaTME the best approach to low rectal cancer in obese individuals? Novel approaches 
to future surgical study designs are required to answer these questions. 
Surgeons will need to use their best judgment in choosing the correct 
technique based on their technical skill set, their knowledge of their own audited 
results and the patient/tumor specific factors. Despite the holy grail of randomized 
trials, not all patients or tumors are equivalent, thereby necessitating a tailored 
approach that suits the needs of each specific patient presentation. As can be seen 
from above, there is a paucity of data that allows for such conclusions to be made. 
Despite this fact, we must continue to observe our own outcomes to guide the best 
oncologic outcome of our selected technique.  
 
5. Non-operative approaches. “Watch and Wait” – The Outsider. R Perez 
Neoadjuvant chemoradiation has been shown to result in complete eradication of 
rectal cancer in the resected specimen in selected patients, known as complete 
pathological response (pCR). In this context patients with a pCR have had excisional 
surgery and would have undergone considerable morbidity, functional consequences 
and frequent need for temporary or permanent stomas even though the specimen 
obtained after resection had no residual cancer 37. In order to avoid the potentially 
unnecessary consequences of radical surgery, attempts were made to identify patients 
with a complete clinical response (cCR) prior to radical surgery, and offer them an 
organ-preserving strategy 38. After identification of the clinical features of cCR 
(whitening of the mucosa, teleangiectasia and the absence of residual ulceration, mass 
or stenosis) patients can be enrolled in a strict follow-up program also known as the 
“Watch and Wait” strategy 39. Initial clinical assessment of response is made at least 
eight weeks after finishing nCRT, allowing for enough time for tumor regression. At 
MRI, a low-signal intensity of the area harbouring the initial cancer (used as an 
estimate to tumor regression grade – mrTRG1) would be consistent with cCR 40, 41.  
The oncological outcomes of the “Watch and Wait” approach in selected 
patients have been shown to be at least similar to radical surgery, but with improved 
functional outcomes, lesser risk for a stoma and perhaps even improved overall 
survival 38, 42, 43. However, clinical and radiological identification of such patients 
remains challenging with frequent early local recurrences (or tumor regrowths) 
underscoring the importance of close surveillance 43, 44. Even so, recurrences have 
been reported to be mostly within the rectal wall (and rarely exclusively mesorectal), 
frequently amenable to salvage resection and general considered without oncological 
compromise compared with initial surgery 44.  
Considering that baseline features may ultimately influence the chances of 
developing a cCR, restricting the use of nCRT to advanced disease (mrCRM+, mrEMVI+ 
or mrN2) will also restrict the number of patients that could potentially benefit from 
avoiding radical surgery, particularly in the setting of abdominoperineal excision (APE) 
resections 45. Therefore, considering the opportunity for organ-preservation after a 
cCR, nCRT may be an attractive alternative for less advanced cancers such as mrT2N0in 
the most distal part of the rectum, where an APE is deemed necessary for “lowness” of 
the tumor. However, considering the current inability to predict response based on 
pre-treatment biopsies, partly due to significant intratumoral heterogeneity, the 
potential benefits of “Watch and Wait” need to be weighted against the potential 
disadvantages of TME after nCRT in the setting of incomplete response in a patient 
with early baseline staged tumor which might have been amenable to curative surgical 
excision 46. 
 6. Attempts to reduce anastomotic leaks. SD Wexner  
Despite many improvements in the quality of rectal cancer surgery, anastomotic leak 
rates remain between 10 and 15% 47, 48. The adverse sequela of such leaks is 
formidable and costly. In the immediate post-operative period, additional medical and 
surgical procedures prolong hospitalization and increase expense. One recent study 
revealed a six-fold increase in 30-day mortality following anastomotic leak 49. Long-
term morbidity includes impaired function, an increased incidence of permanent 
stoma, increased rates of local recurrence and decreased long-term survival.  
While faecal diversion has been shown to decrease the severity of leaks and 
possibly even decrease the incidence of leaks, stomas are associated with their own 
attendant morbidity including dehydration and complications following stoma 
reversal. Recent attempts to decrease the incidence of anastomotic leaks have 
included alternate types of anastomosis such as colonic J pouch and side-to-side 
(Baker) anastomosis as well as improvements in anastomotic technique with 
compression anastomosis. Several publications have clearly demonstrated a very low 
incidence of leak following compression anastomosis 50, 51. Other novel approaches 
have been internal bypass and anastomotic sealants 52, 53. Two large multicentre 
randomized controlled trials failed to show any benefit to anastomotic buttressing 54, 
55. The most promising currently available option is Indocyanine Green (ICG) 
fluorescence angiography 56. Multiple studies have noted that this inexpensive, safe, 
and reliable technique has changed the decision on the proximal resection margin in 
5%-8% of patients and such a strategy been followed by leak rates of 1.4% - 4% 57, 58. 
Because of these impressive results, many surgeons routinely use ICG imaging for all 
distal anastomoses. 
 
7. The future of surgical training. SA Chadi 
As has been highlighted, rectal cancer surgery represents a high stakes procedure with 
perioperative, functional and oncologic implications to inappropriate technique. Many 
learning curve analyses have suggested that it can take well over 50 procedures to 
reach a safe level of competence, even in the most expert of hands. Various society 
endorsed platforms exist to promote new surgical technique such as the Fundamentals 
of Laparoscopic Sugery ® and the LAPCO curriculum. The former has now become a 
requirement for graduation from North American surgical residency programs. The 
LAPCO curriculum is a structured curriculum that allowed for the safe introduction of 
laparoscopic colorectal surgery in the practices of established consultant surgeons.  
 These prior experiences with new surgical techniques have prompted the 
surgical community to advocate for the safe introduction of complex procedures such 
as robotic surgery and more recently, TaTME. Multiple international courses exist for 
this technique, with some run by surgical societies. These courses, as well as some of 
the world’s highest volume TaTME surgeons, have advocated for minimal annual rectal 
cancer volumes as well as a demonstrated expertise in laparoscopic and transanal 
surgery prior to embarking on this new technique. Additionally, a number of 
interactive educational platforms such as the AIS Channel® and the iLappSurgery 
Foundation® have provided additional sources of educational resources through the 
availability of live and previously recorded procedures as well as the availability of 
didactic resources, in mobile formats.  
 These tenants of surgical education and implementation of new techniques 
have also led to the establishment of proctorship programs to encourage newly 
adopting surgeons to seek the assistance of experienced colleagues so as not to 
compromise the oncologic outcomes of patients. Through ethical implementation 
methods, these new techniques can be safely introduced into the practice of 




The International Symposium on the Future of Rectal Cancer Surgery provided a 
singularly unique educational experience for a live global audience of more than 
25.000 viewers from over 100 countries. Combining expert presentations and evidence 
from all members of the multidisciplinary team including the latest and most 
controversial data with simultaneous live demonstration of the four approaches 
allowed ‘virtual’ attendees to directly engage in an evolving educational event. By 
using the AIS Channel® platform, viewers were encouraged to challenge the ‘experts’ 
and participate in a live global debate. This inclusive approach meant that huge areas 
of rectal cancer surgery were discussed, thus enriching the content.  
The data presented, complemented by the live surgery, eloquently 
demonstrated the principles of rectal cancer surgery and how regardless of the 
approach, one must strive for oncological success whilst respecting the functional 
anatomical consequences of pelvic surgery. Each approach, in appropriately 
experienced hands, can lay claim to this but the over-riding message conveyed by all 
participants was that it is unlikely that there is one approach that is ideal for all 
situations. The primary outcome measures used to explain the benefits of surgery in 
the majority of the presentations included some description of the quality of the 
surgical specimen, complication rates and survival data e.g. overall survival and 
disease-free survival. The quality of excision is a near-immediate quality assurance 
measure and a validated outcome measure for survival outcomes 5. Given this 
background, there are specific conditions (patient or tumor-related) that may give one 
approach advantage over another e.g. tumor size, distance from the anal verge, 
patient body mass index. Furthermore, availability of resources may be a further 
consideration where the cost of the procedure may preclude certain approaches and 
direct surgeons towards others. 
The original principles of TME were historically described in the context of open 
surgery and are still considered by most surgeons as the gold standard by which all 
innovative techniques are measured. However, technology has allowed improved 
vision and dexterity beyond the limitations of the human eye and hand, respectively. It 
is not unreasonable to try and develop technology to improve the status quo, but this 
must be done in a safe and controlled manner through peer-review, safety and quality 
assurance. Many of the criticisms directed at robotics and TaTME were similarly 
directed at laparoscopy when first introduced, but it is important to appreciate that 
modern-day surgery has never been under such scrutiny, and the governance 
surrounding new techniques is far more rigid than at the time of Heald’s original 
description of TME. 
Technology will continue to influence the future of surgery but it is unlikely that 
surgeons will be equally adept at all techniques and approaches. This may mean that 
these four techniques become centralised with patients being directed to a surgeon 
proficient in one technique rather than another. However, whichever technique is 
employed the underlying principles of cancer surgery must not be lost and this must 
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COREAN COLOR II ACOSOG 
Z6051 
ALaCaRT 
2006-2009 2003-2010 2008-2013 2010-2014 
Positive pCRM* 
Open 4.1% 10.0% 12.1% 3.0% 
Laparoscopic 2.9% 9.5% 7.7% 6.8% 
p n.s. n.s. n.s n.s. 
Complete TME** 
Open 74.7% 91.5% 95.1% 91.9% 
Laparoscopic 72.4% 88.4% 92.1% 86.5% 
p n.s. n.s. n.s.  
30-day morbidity 
Open 23.5% 37.1% 58.1% - 
Laparoscopic 21.2% 39.8% 57.1% - 
p n.s. n.s. n.s. n.s 
Anastomotic Leak 
Open 0.0% 10.4% 2.1% 3.4% 
Laparoscopic 1.2% 12.5% 2.3% 2.9% 
p n.s n.s. n.s. n.s. 
30-day mortality 
Open 0.0% 1.7% 0.9% 0.8% 
Laparoscopic 0.0% 1.1% 0.8% 0.4% 
p n.s. n.s. n.s. n.s. 
Conversion   1.2% 17.4% 11% 9% 



















































recurrence Laparoscopic 2.6% 5.0% - - 
p n.s. n.s. - - 
3-year disease-free 
survival 
Open 72.5% 70.8% - - 
Laparoscopic 79.2% 74.8% - - 
p n.s. n.s. - - 
3-year overall 
survival 
Open 90.4% 83.6% - - 
Laparoscopic 91.7% 86.7% - - 








*pCRM (Pathological circumferential resection margin); ** TME (Total mesorectal excision); n.s. (Not 
significant) 
